信邦制药
(002390)
| 流通市值：70.36亿 | | | 总市值：73.87亿 |
| 流通股本：18.52亿 | | | 总股本：19.44亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,565,355,757.09 | 3,046,569,827.96 | 1,582,449,461.55 | 6,460,841,315.46 |
| 营业收入 | 4,565,355,757.09 | 3,046,569,827.96 | 1,582,449,461.55 | 6,460,841,315.46 |
| 二、营业总成本 | 4,276,861,231.49 | 2,859,294,464.95 | 1,499,475,395.38 | 6,029,956,602.6 |
| 营业成本 | 3,724,210,514.97 | 2,501,166,385.53 | 1,307,202,145.01 | 5,232,265,213.44 |
| 税金及附加 | 18,996,760.34 | 11,885,860.27 | 6,931,141.48 | 27,426,488.11 |
| 销售费用 | 229,262,839.63 | 146,659,961.12 | 72,869,443.85 | 343,414,000.78 |
| 管理费用 | 287,369,213.5 | 188,429,729.92 | 106,724,419.99 | 394,424,869.4 |
| 研发费用 | 3,824,833.2 | 2,155,422.34 | 865,885.03 | 4,672,953.58 |
| 财务费用 | 13,197,069.85 | 8,997,105.77 | 4,882,360.02 | 27,753,077.29 |
| 其中:利息费用 | 18,569,510.71 | 12,593,004.89 | 6,661,506.72 | 39,698,422.94 |
| 其中:利息收入 | 6,002,045.76 | 4,035,891.14 | 2,017,147.48 | 12,729,596.56 |
| 加:投资收益 | 1,300,500.19 | - | - | 9,397,367.33 |
| 资产处置收益 | -25,311.75 | -9,669.8 | -11,745.36 | 17,801.27 |
| 资产减值损失(新) | - | - | - | -7,523,015.71 |
| 信用减值损失(新) | -25,821,346.09 | -21,706,722.3 | -3,343,367.45 | -53,126,703.33 |
| 其他收益 | 3,296,082.51 | 2,198,410.45 | 977,957.2 | 5,382,978.6 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 267,244,450.46 | 167,757,381.36 | 80,596,910.56 | 385,033,141.02 |
| 加:营业外收入 | 735,020.83 | 595,473.35 | 281,043.64 | 25,010,364.72 |
| 减:营业外支出 | 3,707,307.6 | 2,264,885.7 | 1,287,768.48 | 14,021,913.7 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 264,272,163.69 | 166,087,969.01 | 79,590,185.72 | 396,021,592.04 |
| 减:所得税费用 | 31,534,618.66 | 14,647,709.58 | 7,896,395.34 | 42,249,086.61 |
| 六、净利润 | 232,737,545.03 | 151,440,259.43 | 71,693,790.38 | 353,772,505.43 |
| 持续经营净利润 | 232,737,545.03 | 151,440,259.43 | 71,693,790.38 | 353,772,505.43 |
| 归属于母公司股东的净利润 | 176,589,574.9 | 114,879,289.31 | 58,824,843.56 | 287,232,798.94 |
| 少数股东损益 | 56,147,970.13 | 36,560,970.12 | 12,868,946.82 | 66,539,706.49 |
| (一)基本每股收益 | 0.09 | 0.06 | 0.03 | 0.15 |
| (二)稀释每股收益 | 0.09 | 0.06 | 0.03 | 0.15 |
| 九、综合收益总额 | 232,737,545.03 | 151,440,259.43 | 71,693,790.38 | 353,772,505.43 |
| 归属于母公司股东的综合收益总额 | 176,589,574.9 | 114,879,289.31 | 58,824,843.56 | 287,232,798.94 |
| 归属于少数股东的综合收益总额 | 56,147,970.13 | 36,560,970.12 | 12,868,946.82 | 66,539,706.49 |
| 公告日期 | 2024-10-31 | 2024-08-31 | 2024-04-29 | 2024-04-16 |
| 审计意见(境内) | | | | 标准无保留意见 |